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A B S T R A C T
Size reduction of drug with poor water solubility to nanoscale is an effective way to help improve the efficacy of
drug delivery to the human body. A solid hollow fiber cooling crystallization technique has been adopted to
continuously produce griseofulvin drug nanoparticles under modest conditions with accurate controllability. In
the solid hollow fiber cooling crystallization device, drug solution flowed through the bores of solid hollow fibers
while the cooling liquid was circulated counter-currently in the shell side of the device to cool down the drug
solution in the tube side. Due to intense heat exchange between the cooling liquid and the drug solution through
the thin fiber walls, the temperature of drug solution decreased rapidly so that drug nanoparticles were pre-
cipitated out from the solution by sudden reduction of solubility. Through variation of the experimental con-
ditions and parameters, the mean size of the produced nanoparticles was regulated and controlled. The nano-
particles were dispersed uniformly, the chemical structure and bonds of prepared nanoparticles was the same
with as-received griseofulvin. Both raw material and NPs the polymorph(s) present form I, the melting point was
220 °C. Drug dissolution testing was also executed to verify that nanocrystals have a higher dissolution profile.
1. Introduction
Nanoparticles are of great interests in many fields including theo-
retical magnetics (Sun et al., 2010), cancer drug resistance (Markman
et al., 2013), solar cells (Law et al., 2005), optical sensors (Pouzesh
et al., 2019), drug delivery systems (Allen et al., 2013), biological
systems (Albanese et al., 2012), and antimicrobial activity (Ahmed
et al., 2016). Drug nanoparticles are frequently used in drug delivery
systems due to their distinct properties such as large surface area, high
solubility, excellent carrying capacity, controlled release, targeting to a
special type of cell, and multimodality for diagnostics (Chen et al.,
2016). Each drug has a therapeutic window for the best use of the drug;
however, in some cases, poor water solubility of drugs limits the con-
centration of drugs to the target areas. Due to the unique properties of
nanoparticles, reduction particle size of drug is one of the most pro-
mising way to improve the efficacy of drug delivery (Chen et al., 2011).
Currently, both top-down and bottom-up methods are used to pro-
duce drug nanoparticles (Biswas et al., 2012). Conventional top-down
methods include high-pressure homogenization (HPH), stirred bead
milling (SBM), chemical vapor etching technology, etc. To improve
bioavailability of drugs, the HPH and SBM methods are utilized to
produce uniform nanoparticles using different mechanical strategies:
HPH approach mainly depends on cavitation effect to produce nano-
particles while SBM is brought upon by collisions between milling
media and the solid API particles (Nakach et al., 2018). Duan reported
that chemical vapor etching is used to synthesize nanoparticles with
corrugated-shaped structure (Duan et al., 2018); the corrugated struc-
ture of the nanoparticles showed remarkable stability. Due to high-
energy consumption, high mass loss and cost incurred, the top-down
methods are gradually trending down.
Bottom-up methods generate nanoparticles popularly by precipita-
tion and evaporation methods (Ariga et al., 2007). Dai introduced a
facile method by using SiCl4 as a self-assembled template to synthesize
nano-sized porous silica without etching (Dai et al., 2014). Compared to
conventional methods, this approach costs less and improves the per-
formance of silica via high porosity and large surface area. Spray freeze-
drying (SFD) and supercritical fluid (SCF) approaches are used widely
to synthesis hydrogels (Ali et al., 2009). Using SFD method, the
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hydrogels with the large pores tend to form micrometer scale due to
nucleation and growth of solvent crystals. To reduce the size of aerogel
pore size to nanoscale, Clare froze the sample immediately into small-
size particles and then sublimate it under low pressure to produce nano-
sized hydrogels (Jiménez-Saelices et al., 2017). On the contrary, SCF
technology is beneficial in that a porous structure is better produced
and could conserve the nanoscale product. Supercritical fluids can re-
place organic solvents for their unique properties, such as no toxicity,
low viscosity, reaction under medium temperature and without drying
process, etc. Supercritical fluids have become a popular method to
produce nanoparticles in which supercritical carbon dioxide (SCO2) is
widely used as a solvent of hydrophobic drugs (Tsang et al., 2018); this
method is environmentally beneficial to produce nanoparticles without
any residual solvent. To achieve quicker dissolution, the supercritical
anti-solvent (SAS) process is applied to enhance the solubility of na-
noscale drugs (Park et al., 2014).
However, these technologies for nanoparticle synthesis have short-
comings, such as requirement of large equipment and high pressure.
Atomic layer deposition (ALD) is a useful approach to fabricate nano-
particles, whereas the process is slow and requires expensive vacuum
equipment. Sol gel nanofabrication is applied to synthesize various
materials and cost less, but the reaction is difficult to control. Chemical
vapor deposition may produce toxic gases during the synthesis process
(Biswas et al., 2012). The layer-by-layer assembly method is facile and
affordable, however, the qualities and thicknesses of LBL film depend
largely on experimental conditions such as pH (Ariga et al., 2007).
Machmudah et al. (Machmudah et al., 2016) introduced batch and flow
methods to produce porous zirconia nanoparticles with a SUS tube
under a high pressure of 30MPa. Batch reactor is also a good way to
remove the phenolic compounds by stainless steel metal tube though
cooling crystallization (Kontos et al., 2014). However, the tubes made
of stainless steel are easily corroded without proper coatings (Wang
et al., 2017).
Zarkadas and Sirkar (Zarkadas et al., 2004a; Zarkadas et al., 2004b)
have already demonstrated by solving the governing heat transfer
equations that the temperature differences between the hollow fiber
wall and the crystallizing solution is as low as 1–2 °C due among others
to the very small radial dimensions of the hollow fibers; the corre-
sponding differences in SUS tubes are around 5–10 °C. As a result, one
can have uncontrolled nucleation at different radial locations along the
much larger SUS tube radius leading to a very broad crystal size dis-
tribution. Zarkadas and Sirkar (Zarkadas et al., 2004a) have carried out
already a comparison between a MSMPR crystallizer and a SHFCC de-
vice. Although it would be useful to carry out a SUS tube-based crys-
tallization, it is clear that it will have a much broader CSD than that in a
SHFCC.
To avoid these problems, the solid hollow fiber cooling crystal-
lization (SHFCC) technology (Zarkadas et al., 2004a) is adopted here to
fabricate drug nanocrystals in a continuous operated manner with more
accurate controllability over the product, and increased economic ef-
ficiency. In the SHFCC device, a solution of the drug to be crystallized
flows evenly in the bore of many identical microns-sized solid hollow
fine fibers that could provide accurately controlled micro-environment
for crystallization of nanoparticles; a cold liquid flows on the shell side
of this hollow fine fiber in a countercurrent direction setting up a rapid
and highly efficient heat exchange, thus very high supersaturation is
created instantaneously leading to rapid crystallization of the drug in-
side the entire hollow fibers (Zarkadas et al., 2004a). Compared to
metallic materials, polymeric materials can be much more resistant to
corrosion and dirt accumulation. Polymeric hollow fiber heat ex-
changers can have thermal conductance/volume 3–10 times larger than
shell-and-tube heat exchangers (Zarkadas et al., 2004b). Solid hollow
fiber cooling crystallization devices utilize such solid polymeric hollow
fibers for heat exchange. In the SHFCC device, the drug solution flows
through the bore of solid hollow fibers, while cooling liquid is circu-
lated counter-currently in the shell side of the solid hollow fibers.
Owing to the temperature differential, the drug particles crystallized/
precipitated from feed solution to be collected. Zarkadas used water-
soluble paracetamol as a drug model and found that the mean size of
crystals was impacted by temperature variation of the cooling liquid
(Zarkadas et al., 2007). For this, heat exchange could be used to control
the size easily and had a promising application in the preparation of
nanoparticles. In the previous study (Chen et al., 2016), we have used
the SHFCC method to obtain micron-size drug crystals with the size
around 10 μm in a continuous fashion, as well as continuous polymer
coating of submicron sized silica particles (0.5 μm) by different poly-
mers.
In this study, the SHFCC technique was further developed to pro-
duce nano-sized drug particles of griseofulvin (GF) continuously under
modest conditions, and the product quality could be controlled by the
variation of different parameters. This novel SHFCC device was devel-
oped to produce the drug nanoparticles in a continuous manner which
was in accordance with the FDA’s new policy and industry trend. By
switching to continuous operation, we can produce the product in a
more controllable, economical and accurate way. To have excellent
heat exchange, the size of the inner diameter of solid hollow fibers,
which are key to the SHFCC module, is chosen to be in the millimeter
range. With the size of hollow fibers smaller, the temperature difference
between the fiber centerline and the wall decreased, which generated a
relatively uniform heat exchange conditions; meanwhile the wall
thickness was small enough to help rapid heat transfer through the wall.
The module contained a number of parallelly-placed hollow fibers in-
side the shell to ensure the heat transfer through each hollow fiber can
be carried out simultaneously and efficiently. The scale-up was also
easy to achieve just by proportionally increasing the numbers of hollow
fibers in the tube side. The morphology of particles was measured by
Transmission electron microscopy (TEM) and Scanning electron mi-
croscope (SEM); Raman, X-ray diffractometion (XRD) and Fourier
transform infrared spectrometer (FT-IR) were used to determine the
compositional properties of the particles; Synchronous TG-DSC thermal
analyzer (DSC) was used to compare the thermal properties of the na-
noparticles with those of the as supplied material; the dissolution rate
was also investigated to compared the dissolution property between the
as-received drug and produced nanocrystals of the drug.
2. Materials and methods
2.1. Materials
Griseofulvin (GF, purity 99.2%) drug in the form of particles was
prepared by a batch-type reactor from Yuanchenggongchuang
Technology Co. Ltd (Wuhan, China) and used without any treatment.
Acetone acting as the solvent for GF was purchased from Lvyin
Chemical Co. Ltd (Xiamen, China). An aqueous solution of 95% by
volume of ethanol (95% ethanol) was obtained from Dahao fine
Chemical Co. Ltd (Shantou, China). All materials were used as received.
2.2. Experimental method
As shown in Fig. 1 (a), the SHFCC system was made of four com-
ponents: water bath section; circulating coolant section; heat exchange
section and filtering section. In the water bath section (DF-101S,
Hangzhou Gengyu Instrument Co. Ltd, Hangzhou, Zhejiang, China), the
as-received GF powder was first dissolved in acetone at a saturation
concentration (42.6mg/mL) at a bath temperature of 40 °C with mag-
netic stirring. Using a peristaltic pump, the acetone solution of griseo-
fulvin was introduced through the interior of solid hollow fibers at a
flow rate of 17mL/min (unless otherwise mentioned) at a constant
temperature of 40 °C. At the same time, ethanol (95%) as cooling liquid
at a temperature of −10 °C (unless otherwise mentioned) was circu-
lated counter-currently in the shell side of the hollow fibers. Due to the
quick exchange of heat between the drug solution and the cooling
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liquid through the very thin hollow fiber walls, the temperature of drug
solution decreased rapidly leading to the precipitation of GF nano-
particles. A filter system was placed underneath the device outlet to
collect the drug nanoparticles. The particles were freeze-dried and
stored under the temperature of −20 °C.
A perspective view of solid hollow fibers cooling crystallization
(SHFCC) shown in Fig. 1 (b) exhibited the principle of liquid flow and
heat exchange. As a kernel of heat exchange section in SHFCC system,
the SHFCC module contained 40 solid hollow fibers inside the tube;
these fibers were made of polyetherimide (Sabic PEI Ultem1000) with
an outer diameter (O.D) of 700 μm and an inner diameter (I.D) of
500 μm. These hollow fibers with an effective length of 32 cm were
placed inside a tubular shell, which had an O.D of 1.8 cm.
2.3. Particle characterization
2.3.1. TEM
The GF particle size and morphology were investigated by a trans-
mission electron microscopy (Tecnai G, Spirit, FEI, Hong Kong). For
characterization, the samples were first dispersed homogeneously in
water by using an ultrasonic bath; then a droplet was placed on a
carbon coated TEM grid to allow the evaporation of the solvent.
2.3.2. SEM
Microstructures of samples were investigated with scanning electron
microscope (Supra 55, Zeiss, Oberkochen, Germany). The prepared
particles were dissolved in water, and a drop of suspension was put on a
silica slice and dried in an oven. The samples were observed after
spraying gold in a high vacuum environment for 30 s.
2.3.3. DLS
Dynamic light scattering (DLS) analyzer (Nano-ZS, Malvern
Instruments Ltd, UK) was applied to obtain the mean size and
distribution of the particles. The Brownian motion of particles in dis-
persion produced the fluctuation of scattered light and then the
equipment detected the scattered light. For the detection of particle size
distribution, the sample was dispersed in water at a concentration of
0.5 mg/mL.
2.3.4. XRD
The structural properties of the samples were measured by Ultima
IV X-ray diffractometer (XRD, Rigaku, Matsubara-cho, Japan) and the
wavelength of Cu-Kα radiation was 0.15418 nm, operating at 40 kV and
30mA in 2θ range of 0–40°. The scanning rate was set at 15°/ min with
a step size of 0.02°.
2.3.5. DSC
The thermal analysis of GF particles was investigated with a
Synchronous TG-DSC thermal analyzer (STA 449 F5 Jupiter, Netzsch,
Bavaria, Germany). A sample of 5mg was placed in a hermetically
sealed alumina crucible, in a temperature range of 75 °C to 250 °C with
a ramp of 10 °C/ min. Nitrogen flow rate was set at 20mL/min.
2.3.6. FT-IR
A Fourier transform infrared spectrometer (Bruker, Germany) was
performed to detect whether the chemical groups of samples altered. A
mixture of drug particles and potassium bromide was pulverized by an
agate mortar and dried in an oven before the FT-IR spectra were taken
in the spectral range from 400 to 4000 cm−1.
2.3.7. In vitro dissolution testing
For comparing the dissolution performance between the as-received
GF particles and the produced nanoparticles, a dissolution tester (ZRS-
8GD, Tianjin Tianda Tianfa, Tianjin, China) was operated using the
paddle method to determine the cumulative dissolution of the samples.
With the equipment operated at a rate of 100 rpm under a temperature
(a) Flow diagram of the solid hollow fiber crystallization 
(b) Perspective view of solid follow fiber crystallization module   
Fig. 1. (a) Flow diagram of the solid hollow fiber crystallization process; (b) Perspective view of solid hollow fiber crystallization module.
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of 37 °C, each sample weighing 15mg precisely was added to 500mL
phosphate buffer saline (PBS) with pH of 6.8 in a dissolution cup
(maximum volume of 1 L). At time intervals of 5, 10, 15, 20, 25, 30, 40,
50, 60, 70, 80, 90, 110, 130, 150, 180, 210min, 5mL solution (con-
taining the dissolving sample) was taken out respectively from the cup
and the same amount of fresh PBS was added in. Getting through a filter
with pore diameter of 0.45 µm, the optical density value of solution was
detected by an ultraviolet spectrophotometer (UV-1750, Shimadzu,
Japan) at a wavelength of 292 nm. Compared to a standard curve, the
concentrations at all times were obtained to determine the dissolution
performance of as-received GF and nanoparticles. The dissolution dif-
ference between as-received GF and drug nanocrystals was determined
via similarity factor (f2).
3. Results and discussion
3.1. Characterization of GF nanocrystals
3.1.1. Characterization of morphology and size
Under a flow rate of 17mL/min and T-differential of 50 °C, the size
of particle was determined to be around 200 nm. The optimization
experiments were performed and the yield was about 12.4% while 60%
GF remained in solution. As shown in Fig. 2, the mean particle size of
produced nanoparticles and as-received drug powder were obtained by
dynamic light scattering (DLS) to be 189.8 ± 7.5 nm and
4056 ± 100.5 nm, respectively. The much smaller size of the produced
drug nanoparticles could be attributed to the following reasons: the
very large surface area/volume ratio for the solid hollow fiber mem-
branes could increase the heat transfer efficiency between the cooling
liquid and the drug solution that lead to a rapid precipitation of the
drug nanocrystals; then the small-sized hollow fiber interiors could help
regulate the size of produced nanocrystals before being pumping out to
the outlet. The produced nanocrystals were stored up to 30 days after
the collection, and the particle size of product remain relatively stable
after proper storage as shown in Fig. 3. It is suggested that the thin
hollow fiber walls and their small diameter in the SHFCC device could
accurately control the temperature profile and reduce its variation
across the radial dimension so that the synthesized particle size could
be controlled through the adjustment of operating conditions.
TEM images shown in Fig. 4(a) and Fig. 4(b) illustrate the appear-
ances of prepared nanoparticles and as-received GF. With twentyfold
difference in size, the particle size of drug powder and prepared na-
noparticles (about 200 nm) were in accordance with the result shown in
DLS. The as-received GF showed agglomeration and irregular shape
while the produced drug nanoparticles were dispersed uniformly in the
picture. SEM was further used to measure the morphology and structure
of as-received GF and drug nanoparticles. As shown in Fig. 5(a), the size
of as-received GF was about 4 μm with very thick agglomeration and
rough surface at the magnification scale of 10.00 KX, while the
produced nanoparticles had a particle size around 200 nm with a
smooth crystal structure in Fig. 5(b). Besides, Fig. 5(c) indicated an
excellent dispersity for the drug nanocrystals which further suggested
successful production of fine nanocrystals by the SHFCC device.
3.1.2. Chemical structure analysis
FT-IR result shown in Fig. 6 was used to analyze the chemical
structure and bonds of prepared nanoparticles and the as-received GF.
The results showed that the characteristic peaks at 1460 cm−1,
1504 cm−1, 1802 cm−1 and 1615 cm−1 were derived from the skeleton
vibration (v C=C) of the benzene ring and the presence of peak at
2988 cm−1 was C–H stretching vibration (v C–H). Simultaneously, the
presence of peaks at 1659 cm−1 and 1710 cm−1 were derived from the
characteristic peak of C=O stretching vibration (v C=O). Compared to
as-received GF, the chemical bonds of prepared nanoparticles by SHFCC
device did not make any difference which further suggests that the
synthesized GF nanoparticles retain the same structure as that of the
original drug.
3.1.3. Crystallinity analysis
Results of XRD analysis of prepared nanoparticles and the as-re-
ceived GF shown in Fig. 7 confirmed the crystallinity of nanoparticles.
The polymorph of original griseofulvin was form I (De Gioannis et al.,
2004a; De Gioannis et al., 2004b; Su et al., 2018; Mahieu et al., 2013).
Compared with as-received GF, the location of the peaks in the case of
nanoparticles coincided with those of as-received GF indicating that
there was no crystal form transformation. The polymorph was form I for
both prepared nanoparticles and the as-received GF, suggesting that the
SHFCC process did not alter the crystallinity of the GF drug particles.
Melting temperatures of different griseofulvin polymorphs were
discriminatory, and the temperature of form I was 220 ± 1 °C, form II
was 214 ± 1 °C, form III was 205 ± 1 °C (Mahieu et al., 2013).
Thermal analyses for prepared nanoparticles and as-received GF de-
tected with TG-DSC thermal analyzer determined that the structure of
drug nanocrystals did not change when processed with the SHFCC de-
vice. According to testing results shown in Fig. 8, the DSC curves nearly
overlap except that the melting points had a slight difference for pre-
pared nanoparticles and as-received GF. No significant difference in
melting point indicated crystalline nature of nanoparticles was the same
as that of the as-received GF. However, the peak area of nanoparticles
(about 94.01 J/g) was larger than drug powder (peak area about
71.47 J/g) demonstrating that the prepared nanoparticles had higher
crystallinity, which was in agreement with the XRD result. No obvious
loss of mass or melting points change for prepared nanoparticles were
observed during synchronous TG-DSC thermal analysis.
3.1.4. Dissolution testing
The dissolution and release of drug directly affect the absorption of
Fig. 2. The DLS-based size distribution of nanocrystals and as-received GF
without any treatment.
Fig. 3. The stability test of prepared nanoparticles (mean ± SD, n= 3).
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drug in human body; therefore, dissolution is closely related to the ef-
ficacy of drugs. Compared to the size of as-received GF, nanoscale
particles had a higher specific surface area for their small dimension,
and large contact area further promotes drug dissolution and absorp-
tion as exhibited in Fig. 9 indicating that the drug nanocrystals had a
higher dissolution profile than that of the as-received GF (the experi-
ment was repeated three times). The cumulative dissolution of prepared
nanoparticles reached up to 20% at 5min whereas the as-received GF
crystals required about 40min to reach a cumulative dissolution of
20%. Thus, the dissolution rates at the beginning were higher than
those of as-received micron-scale drug crystals produced by conven-
tional batch reactor for almost an order of magnitude. After as-received
powder dissolution for 180min and 210min, the cumulative release of
powder was up to 54.2% and 54.6% in succession; meanwhile, over
60% prepared nanoparticles dissolved in PBS at 110min and did not
increase remarkably. A statistical analysis was used to determine the
dissolution difference between as-received GF and drug nanocrystals.
The similarity factor f2 can be calculated as
∑= ⎧⎨⎩
+ ⎛
⎝
⎞
⎠
− ⎫
⎬⎭=
−f
n
R T50·log 1 1 [( ) ] ·100
t
n
2
1
t t
2 0.5
(1)
where n was number of time points; Rt was dissolution value of the as-
received GF at time t; Tt was dissolution value of the drug nanocrystals
at time t. The prepared nanoparticles did not exhibit similar drug re-
lease profile compared to that of as-received powder with f2 value of
30.1 which identified there existed statistical significance (p < 0.05)
in the drug release.
Fig. 4. TEM micrographs of (a) nanoparticles fabricated by SHFCC device and (b) as-received GF without any treatment.
Fig. 5. SEM micrographs: (a) as-received GF without any treatment at a magnification of 10.00 KX; (b) prepared GF nanoparticles at a magnification of 20.00 KX; (c)
prepared GF nanoparticles at a magnification of 80.00 KX.
Fig. 6. FT-IR images of prepared nanoparticles and as-received GF without any
treatment.
Fig. 7. XRD patterns of prepared drug nanocrystals and as-received GF without
any treatment.
Q. Liu, et al. International Journal of Pharmaceutics 576 (2020) 118978
5
3.2. The variation of flow rate for drug solution
The flow rate of the drug solution could impact the particle size of
the drug nanocrystals through the change of the residence time for
different flow rates as well as the mixing conditions. Faster flow rate
could reduce the residence time of the crystallization process to de-
crease the particle size. In addition, the mixing condition could be also
intensified due to the high feed side flow velocity inside of the hollow
fibers. Therefore, a series of flow rates (8.5, 17 and 25.5 mL/min) were
utilized as shown in Table 1. Except for flow rate, other factors in ex-
periment remained constant: saturation concentration at 42.56mg/mL;
the temperature of water bath was setting at 40 °C; the temperature of
cooling liquid was set at−15 °C; SHFCC device without any change and
so on.
As shown in Fig. 10, the mean size of the synthesized GF nano-
crystals was 407.2 nm, 276.2 nm and 172.6 nm, respectively under
condition A1, A2 and A3. The results were generally in accordance with
the TEM pictures of Fig. 11. With an increase in the flow rate of the
drug solution, the mean size of nanoparticles decreased gradually on
account of shorter residence time in the hollow fibers. Keeping other
factors constant, the increased flow rate of drug solution led to a
shortened duration of heat exchange, and further impeded the growth
of crystals. Meanwhile at a large flow rate of 25.5mL/min (condition
A3), very low mass of nanoparticles precipitated on a filter paper since
there was not enough time to grow crystals. Compared to the mean size
and morphology of nanoparticles under different flow rate, the particle
surface had no significant change. By simply changing the flow rate of
drug of solution, the yield of nanocrystals increased.
3.3. The variation of cooling temperature of circulating liquid
Cooling temperature of the shell side fluid plays an important part
in the crystallization process since it directly affects the supersaturation
level of the drug solution and the nucleation rate in the lumen side. In
order to study the heat exchange impact due to the change of cooling
temperature, the temperature of cooling liquid was set at 0, −5, −10
Fig. 8. DSC results of prepared drug nanocrystals and as-received GF without
any treatment.
Fig. 9. Cumulative dissolution results of prepared nanocrystals and as-received
GF particles without any treatment (mean ± SD, n=3).
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and −15 °C respectively (namely B1, B2, B3 and B4) in the experi-
ments. Other parameters in experiment remained identical for these
four experimental groups: a saturation concentration at 42.56mg/mL,
the water bath temperature at 40 °C, and the drug solution flow rate at
8.5 mL/min.
Due to the cooling temperature decrease, the temperature differ-
ential increased. As shown in Fig. 12, temperature differential increased
led to an increase in the mean size of nanoparticles. Under conditions
B1, B2, B3 and B4, the mean size of nanoparticles was respectively at
138.3 nm, 172.1 nm, 316.0 nm and 407.2 nm as shown in Table 2. At
low supersaturation, crystals can grow faster than they nucleate re-
sulting in a larger crystal size distribution. However, at higher super-
saturation, crystal nucleation dominated crystal growth, ultimately re-
sulting in smaller crystals. In our experiment, since the drug
griseofulvin was not that sensitive to the temperature reduction, it
produced relatively low supersaturation that led to the larger crystal
size. Moreover, during the initial stage of reaction, it did produce more
nuclei due to larger ΔT induced supersaturation. It was easier for these
many nuclei to agglomerate and grow in the module due to the nature
of continuous liquid flow movement that swept together some of the
drug particles. So larger ΔT could essentially promote the generation
and growth of the nanocrystals under same residence time resulting in
the increase of the particle size and yield.
4. Conclusions
A solid hollow fiber cooling crystallization (SHFCC) technology was
developed to continuously fabricate drug nanocrystals under modest
conditions. A compact module could not only be operated in a con-
tinuous production mode to feed the modern pharmaceutical industry
needs, but also be easily scaled up due to the unique interior design as
proved by the control group. The accurate control of the precipitation
temperature helped precisely adjust the particle size and dispersity of
the produced drug nanocrystals. Besides, it was found that the drug
solution flow rate and the cooling temperature were two critical para-
meters that could largely impact the quality and size of the produced GF
nanocrystals.
Increasing the flow rate of the drug solution from 8.5 mL/min to
25.5 mL/min led to the shortening of the residence time, and further
impeded the nucleation and the growth of drug nanocrystals. With
enlarging temperature differential between the inlet and outlet, the
mean size of nanoparticles increased, however, most of qualities of
nanoparticles remained identical and stable which further suggested
that this cooling crystallization method would not alter the quality of
the original drug.
The SHFCC technology is suggested as suitable for continuous na-
noparticle synthesis with relatively low-energy cost and easy operation
including possible large-scale production. The prepared uniform and
free-flowing drug nanocrystals further demonstrate that the SHFCC
method had a promising application in industrial production of drug
nanoparticles under continuous and controllable condition.
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Particle size of the drug nanocrystals under variation of cooling temperature (n= 3).
Experimental Temperature of water
bath (°C)
Temperature of cooling
liquid (°C)
ΔT (°C) Flow rate for drug
solution (mL/min)
Mean
(nm)
Standard
Deviation (nm)
d10 (nm) D50 (nm) d90 (nm) Yield (%)
B1 40 0 40 8.5 138.3 12.7 109 124 140 7.3
B2 40 −5 45 8.5 172.1 7.3 142 163 189 8.8
B3 40 −10 50 8.5 316.0 18.5 284 329 381 10.7
B4 40 −15 55 8.5 407.2 26.1 299 414 523 13.4
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